Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as VIP943 (QW)
VIP943 · 1 trial · 3 indications
| Arm | Type | Description |
|---|---|---|
| Dose Escalation of VIP943 (QW) | EXPERIMENTAL | Subjects with AML, MDS, and B-ALL with CD123 expression will be administered VIP 943 in sequential ascending doses as a monotherapy via intravenous (IV) administration weekly (QW). |
| Dose Escalation of VIP943 (BIW) | EXPERIMENTAL | Subjects with AML, MDS, and B-ALL with CD123 expression will be administered VIP 943 in sequential ascending doses as a monotherapy via intravenous (IV) administration twice weekly (BIW). |
| Name | Type | Description |
|---|---|---|
| VIP943 (QW) | DRUG | VIP943 will be administered by IV Infusion weekly |
| VIP943 (BIW) | DRUG | VIP943 will be administered by IV Infusion bi-weekly |
Inclusion Criteria: * Histologically confirmed AML, B-ALL or MDS. Subjects must have exhausted all available standard therapies or be deemed ineligible for potential available therapies. * Evidence of ≥5% bone marrow or blood blasts (acute leukemia) or ≥5% bone marrow or blood myeloblasts (MDS) to ...
VIP943 is an investigational small molecule being studied for the treatment of Acute Myeloid Leukemia. It is also being evaluated in patients with B-cell Acute Lymphoblastic Leukemia and High-risk Myelodysplastic Syndrome. The drug is currently in Phase 1 clinical development and has not been approved by the FDA.
VIP943 is being developed by Vincerx Pharma, Inc., a biopharmaceutical company traded on the NASDAQ under the ticker symbol VINC. The company is conducting a Phase 1 clinical trial of VIP943 in patients with advanced CD123+ hematologic malignancies.
VIP943 is currently in Phase 1 clinical development. It is an investigational drug and has not received FDA approval. The ongoing Phase 1 trial is actively recruiting participants in the United States to evaluate the safety and efficacy of VIP943 in patients with certain hematologic malignancies.
VIP943 is being studied in a Phase 1 clinical trial with the identifier NCT06034275. The trial is titled 'Study of VIP943 in Subjects With Advanced CD123+ Hematologic Malignancies' and is currently recruiting participants. The study is enrolling up to 36 patients with Acute Myeloid Leukemia, B-cell Acute Lymphoblastic Leukemia, or High-risk Myelodysplastic Syndrome.
Yes, VIP943 is also known as VIP943 (QW). The designation 'QW' likely refers to a once-weekly dosing schedule being evaluated in the clinical trial. Both names refer to the same investigational drug being developed by Vincerx Pharma for the treatment of hematologic malignancies.